colin md broom  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors colin md broom check out list of companies and businesses related to colin md broom find out colin md broom address and contact details view other people related to colin md broom  coworkers colleagues companions etc address  eagleview boulevard exton  pa companies related to colin md broom cikcompany namepositioncompany addressnps pharmaceuticals incdirector  hills drive bedminster viropharma incvp  chief scientific officer  stockton drive exton nabriva therapeutics plcchief executive officer  fitzwilliam square dublin nabriva therapeutics legacy plcchief executive officer  fitzwilliam square dublin  colin md broom on the web persons related to colin md broom  nps pharmaceuticals incnamepositioncityval r antczaksenior vp legal affairs salt lake cityluke m besharevp  cfo east rutherfordluke m besharbedminsterbiotechnology value fund ii lpchicagobiotechnology value fund l pchicagomichael w bonneydirector lexingtonmichael w bonneydirector salt lake citymichael w bonneydirector bedminstercolin md broomdirector extoncolin md broomdirector bedminstermorgan r brownvice president finance salt lake citymorgan r brownvice president finance salt lake citynancy bryansvp commercial operations bedminsterbvf incilchicagobvf investments llcchicagobvf partners l pilchicagodavid l clarkvp corporate affairs salt lake citydavid l clarkvp corporate affairs salt lake cityn anthony colesceo president and director salt lake cityn anthony colespresident coo  director bedminstersanto j costadirector salt lake citysanto j costadirector salt lake citysandra cottrellvp regulatory affairs  drug bedminsterchristine mikail cvijicsvp legal affairs  gc seattlechristine mikail cvijicsvp legal affairs  gc bedminsterdouglas n dobakbedminsterdouglas n dobakvp regulatory affairs bedminsterjohn robert evansdirector salt lake cityjohn robert evansdirector salt lake citypaul e firutapresident us comm operations bedminsterpaul e firutapresident us comm operations bedminsterrobin d friedmansvp of human resources bedminsterroger garceausvp  cmo bedminsterroger garceausvp  cmo bedminstergeorges gemayeldirector cambridgegeorges gemayeldirector bedminstersusan e grafvpcorp development  strategy bedminsterpedro p granadillodirector pedro p granadillodirector bedminsterjames g groningerdirector salt lake cityjames g groningerdirector salt lake cityjames g groningerdirector bedminsteralan g harrisbedminsteralan g harrissvp chief medical officer bedminsterg thomas heathvp sales and marketing salt lake cityg thomas heathvp marketing and sales salt lake cityhunter jacksonpresident ceo and chairman salt lake cityhunter jacksondirector salt lake cityjames u jensenjames u jensenvp corp dev and legal affairs salt lake cityjoseph klein iiidirector salt lake cityjoseph klein iiidirector salt lake citydonald e kuhladirector salt lake citydonald e kuhladirector salt lake citydonald e kuhladirector bedminsterjuergen lasowskisenior vp business development salt lake citypierre legaultdirector berkeley heightspierre legaultdirector bedminsterthomas b marriott iiivp development research salt lake citythomas b marriott iiivp development research salt lake citymichael e mcdonnellvp human resources salt lake cityglenn r melrosevp human resources salt lake cityglenn r melrosesvp human resources bedminstergerard j michelcfo  vp corp development salt lake citygerard j michelcfo  vp corp development salt lake citygerard j michelcfo  vp corp development bedminsteralan l muellervp discovery research salt lake cityalan l muellervp drug discovery salt lake cityfrancois naderpresident ceo and director salt lake cityfrancois naderpresident ceo and director bedminsteredward f nemethvp  chief scientific officer salt lake cityedward f nemethvp  chief scientific officer salt lake citybrian ocallaghanbedminsterbrian ocallaghansvp  cco bedminsterthomas n parksdirector salt lake citythomas n parksdirector salt lake citystephen r parrishvp manufacturing salt lake citystephen r parrishvp manufacturing salt lake cityeric pauwelspresident nps pharma intl cambridgeeric pauwelspresident nps pharma intl bedminsterandrew d rackearsvp general coun  sec bedminsterandrew d rackearsvp general counsel  sec bedminsteralan mark rauchvp chief medical officer salt lake cityalan mark rauchvp chief medical officer salt lake cityjoseph j rogussvp gto  supply chain mngmt germantownjoseph j rogussvp gto  supply chain mngmt bedminstercottrell sandravp reg affairs  drug safety bedminsterrachel r seliskerdirector salt lake cityrachel r seliskerdirector bedminstercalvin stillerdirector salt lake citycalvin stillerdirector salt lake citycalvin stillerdirector bedminstered stratemeiersvp  general counsel bedminsterpeter g tombrosdirector east rutherfordpeter g tombrosdirector bedminsterpeter g tombrosdirector salt lake citypeter g tombrosdirector salt lake citygregory m torresenior vp regulatory affairs salt lake citypersons related to colin md broom  viropharma incnamepositioncity capital gp llc owner new york capital gp llc owner new york capital gp llc owner new york capital gp llc owner new york capital gp llc owner new yorkavenits holdings incgreenvilleaventis holdings incgreenvilleaventis incbridgewateraventis incaventis incbridgewateraventis pharmaceuticals inc owner bridgewaterbaker biotech capital gp llc owner new yorkbaker biotech capital gp llc owner new yorkbaker biotech capital gp llc owner new yorkbaker biotech capital gp llc owner new yorkbaker biotech capital gp llc owner new yorkbaker biotech capital gp llc owner new yorkbaker biotech capital ii gp llc owner new yorkbaker biotech capital ii gp llc owner new yorkbaker biotech capital ii gp llc owner new yorkbaker biotech capital ii z gp llc owner new yorkbaker biotech capital iii gp llc owner new yorkbaker biotech capital iii z gp llc owner new yorkbaker biotech capital iii z gp llc owner new yorkbaker bros capital gp llc owner new yorkbaker bros capital gp llc owner new yorkbaker bros capital gp llc owner new yorkbaker bros capital gp llc owner new yorkbaker brothers life sciences capital gp llc owner new yorkbaker brothers life sciences capital gp llc owner new yorkfelix bakernew yorkfelix bakernew yorkfelix bakernew yorkjulian bakernew yorkjulian bakernew yorkjulian bakernew yorkbaker tisch capital gp llc owner new yorkbaker tisch capital gp llc owner new yorkbaker  tisch capital gp llc owner new yorkbaker  tisch capital gp llc owner new yorkbaker  tisch capital gp llc owner new yorkfrank baldino jrdirector extonfrank baldino jrdirector extonpaul a brookedirector extoncolin md broomvp  chief scientific officer extoncolin md broomvp  chief scientific officer extoncolin md broomvp  chief scientific officer extonwilliam d md claypooldirector extonwilliam d md claypooldirector extonmarc collettrosen michel derosen michel dechief executive officer extonrosen michel dedirector extonrosen michel dedirector extonmichael r doughertydirector extonmichael r doughertydirector extonthomas f doylethomas f doylevp strategic initiatives extonthomas f doylevp strategic initiatives extonrichard farleyrichard farleyvp human resources extonrobert c fletchervp business development extonrobert glaserdirector extonrobert glaserdirector extonrobert glaserdirector extonjohn j kirbyvp chief accounting officer extonjohn r leonedirector extonjohn r leonedirector extonjulie mchughdirector extonmark mckinlaymark mckinlayvp research  development extonvincent milanovincent milanopresident ceo  cfo extonvincent milanopresident and ceo extonrichard steven morrischief accounting officer extonrichard steven morrischief accounting officer extonhoward h piendirector extonhoward h piendirector extonrobert pietruskovp regulatory  quality extonrobert pietruskovp regulatory  quality extoncharles a rowland jrchief financial officer extoncharles a rowland jrvp chief financial officer extondaniel b solandvp chief operating officer extondaniel b solandvp chief operating officer extonjoshua m tarnoffvp commercial extonjoshua m tarnoffvp chief commerical officer extonjohn peter wolf iiivp general counsel extonjohn peter wolf iiivp general counsel extonpersons related to colin md broom  nabriva therapeutics plcnamepositioncityaxel boltesouth plainfieldcolin md broomchief executive officer extondaniel d burgesssan diegomark corriganmarlboroughrobert crottyseattlesteven p gelonechief development officer king of prussiahbm bioventures cayman ltd owner grand caymansamuel d isalychau quang khuongsan diegoorbimed advisors llcorbimed capital gp v llcnew yorkcharles a rowland jrchadds fordelyse g seltzerchief medical officer king of prussiagary senderchief financial officer new yorkgeorge harrison talbotdirector morristownvivo capital viii llcpalo altostephen w websterextonjohn peter wolf iiiextonpersons related to colin md broom  nabriva therapeutics legacy plcnamepositioncitycarrie l bourdowking of prussiacolin md broomchief executive officer extondaniel d burgessdirector san diegomark corrigandirector marlboroughrobert crottygeneral counsel  corp secreta seattlesteven p gelonechief development officer king of prussiahbm bioventures cayman ltd owner grand caymanchau quang khuongdirector san diegofrancesco maria lavinoking of prussiacharles a rowland jrdirector chadds fordelyse g seltzerchief medical officer king of prussiagary senderchief financial officer new yorkgeorge harrison talbotdirector morristownstephen w websterdirector exton insider trading  broom colin md  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  broom colin md select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing equity swap  pm nana nps pharmaceuticals inc npsp broom colin mddirector   direct view disposition  pm na nps pharmaceuticals inc npsp broom colin mddirector   direct view disposition  pm nana nps pharmaceuticals inc npsp broom colin mddirector   direct view disposition  pm nana nps pharmaceuticals inc npsp broom colin mddirector   direct view option award  pm nana nps pharmaceuticals inc npsp broom colin mddirector   direct view   secformcom all rights reserved archives        sat  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  broom colin md top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active broom colin md • west chester pa how do i update this listing broom colin md is based out of west chester whalewisdom has at least  insider transactions form  in our database for broom colin md summary dg insider form  create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from broom colin md enter your email address below and choose submit your email cancel contact info broom colin md  fringetree drive west chester pa     business phone   sec sic codepharmaceutical preparations recent sec filings  filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on  schedule d and g events since  subscription required form   nonderivative insider transactions since  loading elevate your investments try it for free nabriva  management menu management colin broomchief executive officer colin broom joined nabriva therapeutics in august  he has a bachelor of science degree in pharmacology from university college london and a bachelor of medicine and surgery degree from st george’s hospital medical school london he is a member of the uk royal college of physicians and a fellow of the faculty of pharmaceutical medicine over the past  years colin has been involved in all stages of drug development and commercialization most recently he served as chief scientific officer at viropharma inc now shire previous positions have included a range of leadership positions with amgen hoechst marion roussel now sanofi smithkline beecham and glaxo now glaxosmithklinerobert crottygeneral counselrobert crotty joined nabriva in june  mr crotty joins nabriva with over a decade of experience in the pharmaceutical and biopharmaceutical industries most recently as vp general counsel chief compliance officer and secretary at vernalis therapeutics inc  mr crotty has a broad legal skill set with experience in corporate governance securities filings financing business development corporate law and commercial compliance  previously mr crotty worked in the life sciences industry with positions at dendreon corporation nps pharmaceuticals and imclone systems incorporated  after law school he worked at two law firms morgan lewis  bockius and norton rose fulbright  mr crotty obtained his law degree from the university of pennsylvania and his undergraduate degree from princeton universitysteven gelonechief scientific officer and head of business developmentsteven gelone joined nabriva therapeutics in december  he has a bachelor of sciences and doctorate in pharmacy degree from temple university in philadelphia over the past  years steve has been involved in all stages of drug development and commercialization he has served as head of clinical research and development at spark therapeutics as well as vice president of development at viropharma incorporated now shire previous roles include a leadership positions with gsk vicuron pharmaceuticals and temple university schools of pharmacy and medicine francesco maria lavinochief commercial officerfrancesco maria lavino joined nabriva therapeutics in july  bringing nearly two decades of pharmaceutical sales and marketing experience the last half of his career has been focused on antiinfective medications administered primarily in the hospital setting he most recently served as avp global brand leader antiinfective portfolio at merck  co inc known as msd outside the united states where he was responsible for the development and implementation of the global marketing strategy for the whole merck antibacterial portfolio prior to this role francesco was vp international marketing for the antiinfectives portfolio at cubist pharmaceuticals and previous roles at merck included global brand leadership for the company’s antifungal portfolio and before he held positions in marketing and sales both at regional and country level francesco began his career in pharmaceutical sales at ucb pharma and m in italy he has a bachelor of arts in pharmacy from the federico ii university of napoli italy and an mba from sda bocconi school of management in milan italy elyse seltzerchief medical officerelyse seltzer joined nabriva therapeutics in may  she has a bachelor of arts from the university of pennsylvania and a medical degree from new york university school of medicine she completed her internal medicine training at the university of pennsylvania medical center and her infectious diseases training at yale new haven hospital since  elyse has been involved in all stages of drug development and commercialization most recently she served as vice president global clinical sciences and operations at glaxosmithkline previously she was chief medical officer at tengion and has held leadership positons at centocor vicuron where she led the development of dalbavancin and at smithkline beechamgary senderchief financial officer gary sender has over  years of financial leadership experience in the pharmaceutical and biopharmaceutical industries most recently as chief financial officer and evp at synergy pharmaceuticals from  mr sender served as senior vice president finance at shire plc supporting its specialty pharmaceuticals business and subsequently its global commercial businesses he was responsible for financial management and support of all commercial areas of shire’s  billion specialty pharmaceutical and rare disease businesses with an emphasis on resource allocation financial forecasting business cases and ma prior to joining shire he was the founding cfo of tengion – a biotechnology company in the field of regenerative medicine mr sender spent  years in a number of leadership roles within merck including investor relations ma finance treasury and divisional financial management mr sender holds a bachelor’s degree in finance and information systems from boston university and a master’s degree in industrial administration mba with a concentration in finance from carnegiemellon universitydavid garrettvice president corporate controller and head of investor relationsdave joined nabriva in november  he held previous finance roles with covis pharma auxilium shire and viropharma dave started his career in public accounting with kpmg and is a certified public accountant dave received his bachelor of science and master of business administration degrees from villanova university he is a member of the fei aicpa and picpawerner heilmayervice president research cmc  ipwerner heilmayer joined nabriva therapeutics in february  he holds a phd in organic chemistry having worked for almost  years in the pharmaceutical and biotech industry werner has gained significant experience in drug development and intellectual property he has a strong track record in patent filing and is coinventor of more than  international filed patent applications before joining nabriva werner held the position of head of chemistry of sandozs discovery unit werner played a major role in the nabriva spinoff from sandoz and served nabriva as head cmc and ip before he was appointed vp cmc  ip in june ernie kellyvice president qualityernest kelly joined nabriva therapeutics full time in june  he has a bachelor of arts degree in chemistry from millersville university and a phd in physical chemistry from villanova university over the past  years ernie has been involved in all stages of pharmaceutical development and commercialization most recently as vice president quality at shire plc previous roles include leadership and technical positions in quality and compliance with viropharma now shire cephalon biotechnology general corp rhone poulenc rorer now sanofi merck and mcneil pharmaceutical companies ernie has been active in pharmaceutical trade associations and is a past chair of several phrma technical committees past industry representative on usp aerosol advisory panels and a past adjunct professor of pharmaceuticals temple university school of pharmacythomas lembckchief information officerthomas lembck joined nabriva therapeutics full time in july   for  years he led the it and facility teams at viropharma incorporated building a global organization to support the rapid growth of the organization and supported the company’s acquisition transition into shire plc   prior to viropharma he worked with visalign where he led various teams and projects focused on information systems and strategic planning for pharmaceutical companies including scheringplough pfizer and merck  thomas also has held multiple roles of escalating responsibility at comptek research raytheon and abb in zurich switzerland  at nabriva he has demonstrated technology leadership by crafting the requisite strategic vision to achieve business goals by offering a unique blend of executive acumen global teambuilding and it solutions development with strong roi and operational effectiveness  thomas holds a master of business administration degree from temple university a bachelor of science degree from rensselaer polytechnic institute in electrical engineering and several executive training certificates from both the bell leadership program at university of north carolina and dartmouth’s tuck business school william sargentvice president commercial strategywill sargent joined nabriva september  mr sargent joins nabriva with over two decades of experience in the biopharmaceutical industry including leadership roles for multiple product and line extension launches and as a sellside analyst on wall street most recently he served as vice president orthopedic business unit at auxilium pharmaceuticals now endo international where he led the companys marketing and sales team advancing xiaflex® for the treatment of dupuytrens contracture and development of additional pipeline indications mr sargent received his bachelor of arts in biology from johns hopkins university and an mba from the university of washington secgems broom colin md data feeds now available excel  csv  java  python etc database learn more broom colin md info ownership filings  ←    → filings    of   total  june    issuer nabriva therapeutics plc nbrv reporting owner broom colin md  director officer chief executive officer  signed by gary l sender by power of attorney preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending june   ordinary shares j  other acqui or dispo  shares x sh total owned  ordinary shares j  other acqui or dispo  shares x sh total owned   by grantor retained annuity trust  stock option j  other acqui or dispo  shares x sh total owned   underlying securities ordinary shares   shares stock option j  other acqui or dispo  shares x sh total owned   underlying securities ordinary shares   shares stock option j  other acqui or dispo  shares x sh total owned   underlying securities ordinary shares   shares stock option j  other acqui or dispo  shares x sh total owned   underlying securities ordinary shares   shares feb    issuer nabriva therapeutics ag nbrv reporting owner broom colin md  officer chief executive officer  signed by gary l sender by power of attorney preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending feb   stock option a  grant  award  shares x sh total owned   underlying securities common shares   shares dec    issuer nabriva therapeutics ag nbrv reporting owner broom colin md  officer chief executive officer  signed by gary l sender by power of attorney preview view filing   nc xml  ownership initial statement of beneficial ownership of securities insider trading  directors officers significant shareholders  period ending dec   common shares total owned  common shares total owned   by grantor retained annuity trust  stock option  underlying securities common shares   shares stock option  underlying securities common shares   shares stock option  underlying securities common shares   shares feb    issuer nps pharmaceuticals inc npsp reporting owner broom colin md  director  signed by colin broom by jill thompson as attorneyinfact preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending feb   common stock u  disp in a change of control trans  shares x sh total owned  stock options right to buy d  disp to issuer  shares total owned   underlying securities common stock   shares restricted stock units d  disp to issuer  shares total owned   underlying securities common stock   shares deferred stock units d  disp to issuer  shares total owned   underlying securities common stock   shares feb    issuer nps pharmaceuticals inc npsp reporting owner broom colin md  director  signed by colin broom by jill thompson as attorneyinfact preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending feb   restricted stock units a  grant  award  shares x sh total owned   underlying securities common stock   shares feb    issuer nps pharmaceuticals inc npsp reporting owner broom colin md  director  signed by colin broom by jill thompson as attorneyinfact preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending feb   common stock m  exer or conv of deriv security exempted  shares total owned  restricted stock units a  grant  award  shares x sh total owned   underlying securities common stock   shares restricted stock units m  exer or conv of deriv security exempted  shares x sh total owned   underlying securities common stock   shares jan    issuer viropharma inc vphm reporting owner broom colin md  officer vp  chief scientific officer  signed by j peter wolf attorneyinfact preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending jan   common stock u  disp in a change of control trans  shares x sh total owned  common stock a  grant  award  shares total owned  common stock d  disp to issuer  shares total owned  employee stock option right to buy d  disp to issuer  shares total owned   underlying securities common stock   shares employee stock option right to buy d  disp to issuer  shares total owned   underlying securities common stock   shares employee stock option right to buy d  disp to issuer  shares total owned   underlying securities common stock   shares employee stock option right to buy d  disp to issuer  shares total owned   underlying securities common stock   shares employee stock option right to buy d  disp to issuer  shares total owned   underlying securities common stock   shares employee stock option right to buy d  disp to issuer  shares total owned   underlying securities common stock   shares employee stock option right to buy d  disp to issuer  shares total owned   underlying securities common stock   shares employee stock option right to buy d  disp to issuer  shares total owned   underlying securities common stock   shares employee stock option right to buy d  disp to issuer  shares total owned   underlying securities common stock   shares employee stock option right to buy d  disp to issuer  shares total owned   underlying securities common stock   shares employee stock option right to buy d  disp to issuer  shares total owned   underlying securities common stock   shares employee stock option right to buy d  disp to issuer  shares total owned   underlying securities common stock   shares employee stock option right to buy d  disp to issuer  shares total owned   underlying securities common stock   shares jan    issuer viropharma inc vphm reporting owner broom colin md  officer vp  chief scientific officer  signed by j peter wolf attorneyinfact preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending jan   common stock m  exer or conv of deriv security exempted  shares x sh total owned  common stock f  pmt of exercise price or tax liab  shares x sh total owned  common stock m  exer or conv of deriv security exempted  shares x sh total owned  common stock f  pmt of exercise price or tax liab  shares x sh total owned  common stock m  exer or conv of deriv security exempted  shares x sh total owned  common stock f  pmt of exercise price or tax liab  shares x sh total owned  common stock m  exer or conv of deriv security exempted  shares x sh total owned  common stock f  pmt of exercise price or tax liab  shares x sh total owned  common stock m  exer or conv of deriv security exempted  shares x sh total owned  common stock f  pmt of exercise price or tax liab  shares x sh total owned  common stock m  exer or conv of deriv security exempted  shares x sh total owned  common stock f  pmt of exercise price or tax liab  shares x sh total owned  common stock m  exer or conv of deriv security exempted  shares x sh total owned  common stock f  pmt of exercise price or tax liab  shares x sh total owned  common stock m  exer or conv of deriv security exempted  shares x sh total owned  common stock f  pmt of exercise price or tax liab  shares x sh total owned  incentive stock option right to buy m  exer or conv of deriv security exempted  shares x sh total owned   underlying securities common stock   shares employee stock option right to buy m  exer or conv of deriv security exempted  shares x sh total owned   underlying securities common stock   shares employee stock option right to buy m  exer or conv of deriv security exempted  shares x sh total owned   underlying securities common stock   shares employee stock option right to buy m  exer or conv of deriv security exempted  shares x sh total owned   underlying securities common stock   shares employee stock option right to buy m  exer or conv of deriv security exempted  shares x sh total owned   underlying securities common stock   shares employee stock option right to buy m  exer or conv of deriv security exempted  shares x sh total owned   underlying securities common stock   shares employee stock option right to buy m  exer or conv of deriv security exempted  shares x sh total owned   underlying securities common stock   shares employee stock option right to buy m  exer or conv of deriv security exempted  shares x sh total owned   underlying securities common stock   shares june    issuer viropharma inc vphm reporting owner broom colin md  officer vp  chief scientific officer  signed by j peter wolf attorneyinfact preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending june   employee stock option right to buy a  grant  award  shares total owned   underlying securities common stock   shares feb    issuer nps pharmaceuticals inc npsp reporting owner broom colin md  director  signed by edward stratemeier as attorneyinfact preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending feb   restricted stock units a  grant  award  shares x sh total owned   underlying securities common stock   shares feb    issuer nps pharmaceuticals inc npsp reporting owner broom colin md  director  signed by edward stratemeier as attorneyinfact preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending feb   common stock j  other acqui or dispo  shares total owned  common stock s  open market or private sale  shares x sh total owned  jan    issuer viropharma inc vphm reporting owner broom colin md  officer vp  chief scientific officer  signed by j peter wolf attorneyinfact preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending jan   employee stock option right to buy a  grant  award  shares total owned   underlying securities common stock   shares dec    issuer viropharma inc vphm reporting owner broom colin md  officer vp  chief scientific officer  signed by j peter wolf attorneyinfact preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending dec   common stock m  exer or conv of deriv security exempted  shares x sh total owned  incentive stock option right to buy m  exer or conv of deriv security exempted  shares x sh total owned   underlying securities common stock   shares dec    issuer viropharma inc vphm reporting owner broom colin md  officer vp  chief scientific officer  signed by j peter wolf attorneyinfact preview view filing  a nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending dec   common stock s  open market or private sale  shares x sh total owned  dec    issuer viropharma inc vphm reporting owner broom colin md  officer vp  chief scientific officer  signed by j peter wolf attorneyinfact preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending dec   common stock m  exer or conv of deriv security exempted  shares x sh total owned  common stock s  open market or private sale  shares x sh total owned  incentive stock option right to buy m  exer or conv of deriv security exempted  shares x sh total owned   underlying securities common stock   shares dec    issuer viropharma inc vphm reporting owner broom colin md  officer vp  chief scientific officer  signed by j peter wolf attorneyinfact preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending dec   common stock m  exer or conv of deriv security exempted  shares x sh total owned  common stock s  open market or private sale  shares x sh total owned  common stock m  exer or conv of deriv security exempted  shares x sh total owned  common stock s  open market or private sale  shares x sh total owned  common stock m  exer or conv of deriv security exempted  shares x sh total owned  common stock s  open market or private sale  shares x sh total owned  employee stock option right to buy m  exer or conv of deriv security exempted  shares x sh total owned   underlying securities common stock   shares employee stock option right to buy m  exer or conv of deriv security exempted  shares x sh total owned   underlying securities common stock   shares employee stock option right to buy m  exer or conv of deriv security exempted  shares x sh total owned   underlying securities common stock   shares june    issuer viropharma inc vphm reporting owner broom colin md  officer vp  chief scientific officer  signed by j peter wolf attorneyinfact preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending june   employee stock option right to buy a  grant  award  shares total owned   underlying securities common stock   shares may    issuer nps pharmaceuticals inc npsp reporting owner broom colin md  director  signed by edward stratemeier as attorneyinfact preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending may   deferred stock units a  grant  award  shares x sh total owned   underlying securities common stock   shares feb    issuer nps pharmaceuticals inc npsp reporting owner broom colin md  director  signed by edward stratemeier as attorneyinfact preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending feb   common stock a  grant  award  shares x sh total owned  jan    issuer nps pharmaceuticals inc npsp reporting owner broom colin md  director  signed by edward stratemeier as attorneyinfact preview view filing   nc xml  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  period ending jan   deferred stock units a  grant  award  shares x sh total owned   underlying securities common stock   shares db colin broom md  biography log in email password remember forgot password  become a member for free sign up sign up new membersign up for free new customerdiscover our portfolios united states united kingdom france deutschland schweiz de suisse fr settings dynamic quotes  offon markets equities north americaeuropeasiaoceaniamiddle east� more equities indexes dow jonessp nasdaq tsx compftse � more indexes currency  forex eur  usdgbp  usdusd  jpyusd  cadaud  usd� more currencies commodities goldcrude oil wticrude oil brentsilverplatinum� more commodities news latest news companiesmarketseconomycurrency  forexcommoditiesinterest ratesbusiness leadersfinancial calendareconomic calendar listed company analyst recorumorsiposcapital markets transactionsnew contractsprofits warningsappointmentspress releaseseventscorporate actions sector news energybasic materialsindustrialsconsumer cyclicalconsumer noncyclicalfinancialshealthcaretechnologytelecommunications servicesutilities analysis all analysiscommentariesindex analysisstock trading strategiescommodity analysisforex analysis stock picks all stock picks portfolios my portfolio virtual portfolios traders portfolios european portfoliousa portfolioasian portfolio screeners market screener homefundamental analyse top investor ratingtop trading ratingtop consensusgrowth stocksyield stockslow valuations technical analysis oversold stocksoverbought stocksclose to resistancesclose to supportsaccumulation phasemost volatile stocks watchlists my watchlists watchlists top lists yield stocksgrowth stocksundervalued stocks top  flop top news most read newshot news top fundamentals top capitalizationtop yieldtop pertop consensustop fundamentals top technicals top rsiunusual volumestop gapstop stim top movers top usatop canadatop uktop germanytop europetop asia tools market screenerdynamic chartfinancial calendareconomic calendarsector researchcurrency converter our services premium accessdiscover our services traders homepage    news    business leaders    business leaders biography business leaders latest newscompaniesmarketseconomy  forexcommoditiesinterest ratesbusiness leadersfinance professionalscalendarsectors homeall newsmost read newsbusiness leaders biography colin broom md age  public asset   usdlinked companies  nabriva therapeutics plc  adr  nps pharmaceuticals inc summary  dr colin broom md is a member at royal college of physicianshe is on the board of directors at nabriva therapeutics ag nps pharmaceuticals inc and nabriva therapeutics plc dr broom was previously employed as chief scientific officer  vice president by viropharma inc vpeuropean clinical development  medical affairs by amgen inc senior vice presidentglobal clinical development by hoechst marion roussel inc and vice president by the gi co inche received his undergraduate degree from the university college london and a doctorate degree from st georges university of london current positions of colin broom md  nametitle since nabriva therapeutics plc  adrbiotechnology  medical research chief executive officer  director  nps pharmaceuticals inc independent director nabriva therapeutics ag chief executive officer  director royal college of physicians member  holdings of colin broom md  nameequitiesvaluation nabriva therapeutics plc usd colin broom md personal network  namelinked companies robert l crotty nabriva therapeutics plc  adrnabriva therapeutics agnps pharmaceuticals inc daniel d burgess nabriva therapeutics plc  adrnabriva therapeutics ag axel bolte nabriva therapeutics plc  adrnabriva therapeutics ag mark h n corrigan nabriva therapeutics plc  adrnabriva therapeutics ag chau quang khuong nabriva therapeutics plc  adrnabriva therapeutics ag gary l sender nabriva therapeutics plc  adrnabriva therapeutics ag stephen w webster nabriva therapeutics plc  adrnabriva therapeutics ag charles a rowland nabriva therapeutics plc  adrnabriva therapeutics ag elyse g seltzer nabriva therapeutics plc  adrnabriva therapeutics ag george harrison talbot nabriva therapeutics plc  adrnabriva therapeutics ag most read news   charles schwab  lowfee blackrock funds reel in cash but earnings disappoint djcharles scharf  bank of new york mellon names former visa executive scharf ceo and chairman  philip green  youre hired  uk apprentice star brady to chair philip greens company djrupert murdoch  tesla names james murdoch and linda johnson rice to board  update djjames murdoch  tesla names james murdoch and linda johnson to board of directors djmark light  top company news of the day djnelson peltz  peltz goes on offense in break from form  wsj  david henry  didnt pay your macys bill expect a text from citigroup djmark light  top company news of the day djnelson peltz  peltz seeks pg board seat  wsj more news   people and ownership     advertisement colin broom md  connections  blueprint medicines corp charles a rowland nabriva therapeutics plc  adr robert l crottydaniel d burgessaxel boltemark h n corriganchau quang khuonggary l senderstephen w webstercharles a rowlandelyse g seltzergeorge harrison talbot viking therapeutics inc stephen w webstercharles a rowland ophthotech corp axel bolte spark therapeutics inc stephen w webster cidara therapeutics inc daniel d burgess pieris pharmaceuticals inc chau quang khuong novelion therapeutics inc usa mark h n corrigan cardiome pharma corp mark h n corrigan atoxbio inc daniel d burgess synlogic inc chau quang khuong allena pharmaceuticals inc axel bolte inspire medical systems inc chau quang khuong kolltan pharmaceuticals inc axel bolte nabriva therapeutics ag robert l crottydaniel d burgessaxel boltemark h n corriganchau quang khuonggary l senderstephen w webstercharles a rowlandelyse g seltzergeorge harrison talbot sv life sciences advisers llp daniel d burgess cerapedics inc chau quang khuong lux biosciences inc axel bolte nextcure inc chau quang khuong hbm partners ag investment management axel bolte popular business leaders  bernard arnault mary barra lloyd blankfein michael bloomberg yannick bollor� warren buffett antony burgmans jeanpaul clozel gary cohn jamie dimon ralph dommermuth sebastian ebel john edwards david einhorn jeff fettig mark fields carlos ghosn terry gou david henry carl icahn michel landel daniel loeb jack ma john mackey marissa mayer lakshmi mittal oscar munoz rupert murdoch elon musk peter nicholas john paulson nelson peltz georges plassat hasso plattner thomas rabe giuseppe recchi wolfgang reitzle urs rohner wilbur ross charles schwab igor sechin pascal soriot george soros rupert stadler bernard tapie john williamson thomas wilson dieter zetsche mark zuckerberg az business leaders traderscom marketsnewsanalysisstock picksportfoliosscreenerswatchliststop  floptoolsour servicesabout surperformance sascontact usadvertiselegal informationsabout usstay connected facebooktwitterpartners b�rse aktien kurse und nachrichtenbest tweets copyright �  surperformance all rights reserved slave broom by philippe starck broom by starckbroom is reclaimed recyclable – and designed to last made in america from  waste polypropylene and  reclaimed wood fiber that would normally be swept into the trash that’s why we call it broom newarrivalbroom stacking chair    colorsnewarrivalbroom  counter stool    colorsnewarrivalbroom  barstool    colors film broom a short film broom stacking chair biomuseo panama by frank gehry photo geteca download here broom stacking chair carben restaurant ottawa canada by one design download here broom  counter stool courtepaille olivet france by philippe avanzi download here broom stacking chair new baltimore design school baltimore md by ziger snead download here broom  barstool the armory show champagne lounge nyc by bade stageberg cox download here broom stacking chair private residence atlanta ga photo andrew thomas lee download here story emeco  philippe starckthe story materials bits and piecesread more about reclaimed wood polypropylene  inch by jasper morrison product variations various finishes navy collection product variations  finishes navy collection with wood seat product variations  wood options navy chair with cocacola color variationsnavy upholstered collection product variations  finishes by bmw product variations  color options by norman foster product variationsalfi by jasper morrison product variations  color optionsbroom by philippe starck product variations  color optionsemeco stool by philippe starck product variations  finishesoccasional table by philippe starck product variationsheritage by philippe starck product variations  finisheshudson by philippe starck product variations  finishesicon by philippe starck product variations  finisheskong by philippe starck product variations  finisheslancaster by michael young product variations  color optionsnine by ettore sottsass product variations  color optionsparrish by konstantin grcic product variations  seat optionsrun by sam hecht and kim colin product variations  finishessezz by christophe pillet product variationssoso by jean nouvel product variationssu by nendo product variations  color optionssuperlight by frank gehry product variationcafé table by starck stock screener  yahoo financehomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoreyahoosearchsearchus markets closedsp  dow  listenaetnas ceo mark bertolini on the future of the health care systembertolini shares how a lifethreatening injury shaped his views on health careinsider transactionsdefault criteriainsider  restricted shareholder transactions of  resultsresults were generated a few mins ago pricing data is updated frequently currency in usdsymboldatesharesproceedstransaction detailsnbrvnaacquisition non open market at  per sharenbrvnaacquisition non open market at  per sharenbrvnanastatement of ownershipnbrvnanastatement of ownershipa former biotech executive whos living with terminal cancer wants to reset expectations about new cancer treatmentsbusiness insider dudes in a car blissing out in the lincoln continentalyahoo financewhy it might be ‘dangerous’ for ibm to turn itself around professoryahoo financeyahoo small businessdata disclaimerhelpsuggestionsprivacyabout our adsterms updated